ReviewCell death & disease2012
Role of the promyelocytic leukaemia protein in cell death regulation.
Review in Cell death & disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Review
- MICONIDINE acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells.Investigational new drugs · 2019Article
- Article
- Role of the nucleus in apoptosis: signaling and execution.Cellular and molecular life sciences : CMLS · 2015Review
- Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells.International journal of molecular sciences · 2015Article
- The function, regulation and therapeutic implications of the tumor suppressor protein, PML.Cell & bioscience · 2015Review
- Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding.Journal of hematology & oncology · 2014Article
- Cellular senescence and protein degradation: breaking down cancer.Cell cycle (Georgetown, Tex.) · 2014Article
- Senescence and aging: the critical roles of p53.Oncogene · 2013Review
- Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab.Cell cycle (Georgetown, Tex.) · 2013Article
- Targeting survival pathways in chronic myeloid leukaemia stem cells.British journal of pharmacology · 2013Review
- Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever.Antiviral research · 2013Review
- New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers.Frontiers in oncology · 2013Article
- Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.Hematology. American Society of Hematology. Education Program · 2013Review
- Restoring PML tumor suppression to combat cancer.Cell cycle (Georgetown, Tex.) · 2012Article
- Regulation of the tumor suppressor PML by sequential post-translational modifications.Frontiers in oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The promyelocytic leukaemia gene PML was originally identified at the t(15;17) translocation of acute promyelocytic leukaemia, which generates the oncogene PML-retinoic acid receptor α. PML epitomises a subnuclear structure called PML nuclear body. Current models propose that PML through its scaffold properties is able to control cell growth and survival at many different levels. Here we discuss the current literature and propose new avenues for investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.